Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALA NASDAQ:DRRX NASDAQ:MRUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00+33.3%$0.00$0.00▼$0.00$2K-1.32767 shs1,132 shsDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AMRUSMerus$90.00-7.1%$93.01$37.92▼$97.14$6.83B1.061.51 million shs2.73 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%+50.00%0.00%+200.00%DRRXDURECT0.00%0.00%0.00%0.00%+176.01%MRUSMerus0.00%0.00%0.00%0.00%+69.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00+33.3%$0.00$0.00▼$0.00$2K-1.32767 shs1,132 shsDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AMRUSMerus$90.00-7.1%$93.01$37.92▼$97.14$6.83B1.061.51 million shs2.73 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%+50.00%0.00%+200.00%DRRXDURECT0.00%0.00%0.00%0.00%+176.01%MRUSMerus0.00%0.00%0.00%0.00%+69.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/ADRRXDURECT 2.00HoldN/AN/AMRUSMerus 2.00Hold$95.936.59% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/ADRRXDURECT$1.66M35.80N/AN/A$0.29 per share6.59MRUSMerus$36.13M188.94N/AN/A$9.46 per share9.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/AN/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)DRRXDURECT-$8.32M-$0.10N/AN/AN/A-96.19%-259.16%-71.78%N/AMRUSMerus-$215.33M-$5.30N/AN/AN/A-673.31%-52.99%-44.61%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/ADRRXDURECTN/A0.980.95MRUSMerusN/A7.977.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ADRRXDURECT28.03%MRUSMerus96.14%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%DRRXDURECT3.20%MRUSMerus3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences603.86 million4.55 millionNot OptionableDRRXDURECT8031.05 million30.06 millionOptionableMRUSMerus3775.85 million73.04 millionOptionableDRRX, CALA, and MRUS HeadlinesRecent News About These CompaniesMRUS Share News TodayJune 2, 2026 | uk.investing.comLeonaBio Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comMerus Power Delivers an Energy Storage System for Extreme Arctic ConditionsFebruary 11, 2026 | businesswire.comInsider Buying: Merus (NASDAQ:MRUS) Major Shareholder Purchases 2,978 Shares of StockDecember 31, 2025 | insidertrades.comMerus Completes Genmab Acquisition and Delists From NasdaqDecember 30, 2025 | tipranks.comMerus (NASDAQ:MRUS) Major Shareholder A/S Genmab Purchases 15,710 SharesDecember 30, 2025 | insidertrades.comMerus (NASDAQ:MRUS) Major Shareholder A/S Genmab Purchases 66,264 SharesDecember 23, 2025 | insidertrades.comA/S Genmab Purchases 120,752 Shares of Merus (NASDAQ:MRUS) StockDecember 19, 2025 | insidertrades.comMerus acquired by Genmab, leadership changes announcedDecember 13, 2025 | msn.comGenmab Completes Acquisition of Merus N.V. to Bolster Oncology PortfolioDecember 12, 2025 | tipranks.comGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodDecember 12, 2025 | businesswire.comGenmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodDecember 12, 2025 | globenewswire.comInsider Selling: Merus (NASDAQ:MRUS) VP Sells 1,700 Shares of StockDecember 11, 2025 | insidertrades.comMerus Shareholders Approve Genmab Acquisition ProposalDecember 9, 2025 | tipranks.comMerus N.V. (MRUS): A Bull Case TheoryDecember 5, 2025 | finance.yahoo.comMerus NV (MRUS): A bull case theoryDecember 4, 2025 | msn.comAssessing Merus (MRUS) Valuation Following Recent Share Price SurgeNovember 30, 2025 | finance.yahoo.comHarry Shuman Sells 8,300 Shares of Merus (NASDAQ:MRUS) StockNovember 29, 2025 | insidertrades.comMerus (MRUS) Gets a Buy from Bank of America SecuritiesNovember 25, 2025 | theglobeandmail.comBarclays Sticks to Its Hold Rating for Merus (MRUS)November 25, 2025 | theglobeandmail.comMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026MongoDB's AI Advantage Is Starting to Show Up in ResultsBy Thomas Hughes | May 30, 2026DRRX, CALA, and MRUS Company DescriptionsCalithera Biosciences NASDAQ:CALA$0.0004 +0.00 (+33.33%) As of 02:16 PM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.DURECT NASDAQ:DRRXDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Merus NASDAQ:MRUSMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy CrowdStrike Before the Stock Split? Here's the Case USA Today's Digital Revival Is Gaining Steam, But With Plenty of Risk Burlington Is Winning Over Shoppers But Investors Need Patience Investors Are Buying Into Sweetgreen Again—Should They? MarketBeat Week in Review – 06/15 - 06/19 Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE? Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
